학술논문
A Comparative Study Between Cefodizime (CDZM) and Cefotaxime (CTX) in Respiratory Tract Infections / 呼吸器感染症に対するCefodizime (CDZM) とCefotaxime (CTX) の薬効比較試験
Document Type
Journal Article
Author
Akihito MURATA; Akimitsu KAMITSUNA; Akio HIRAYAMA; Akio ONAKA; Akira ITO; Akira MURAOKA; Akira SAITO; Akira WATANABE; Akira YASUOKA; Atsushi SAITO; Atsushi TAKAHASHI; Eiji INOUE; Fumiaki KINUGAWA; Fumio MATSUMOTO; Fumio MIKI; Fuyuhiko HIGASHI; Hajime NISHIYA; Harumi SHISHIDO; Hideaki SHIGENO; Hidekazu HANAKI; Hideki IKEDA; Hideo IKEMOTO; Hideo MASHIMOTO; Hideo MIYASHITA; Hideo SASAKI; Hiroaki HIRAI; Hirofumi FUKUHARA; Hiroichi TANIMOTO; Hiromi KANAYAMA; Hironobu KOGA; Hiroshi KAWABE; Hiroshi KAWANE; Hiroshi KOBAYASHI; Hiroshi KURAMITSU; Hiroshi OSHITANI; Hirotoshi MINAKAMI; Hiroyuki KOBAYASHI; Hiroyuki KUMANO; Hiroyuki NUMATA; Hisashi INOUE; Ichiro NAKAYAMA; Ikuo KAMIGAKI; Ippei FUJIMORI; Izumi HAYASHI; Izumi YAMAKI; Jingoro SHIMADA; Jiro HINO; Joichi KATO; Jun GOTO; Kaneo SUZUKI; Kanzo SUZUKI; Kaoru OYAMA; Kaoru SHIMADA; Katsuhiro OKAMOTO; Katsumi ENDOU; Katsunori UENO; Katsura MORIYA; Kazufuto FUKAYA; Kazuhide YAMAMOTO; Kazumichi MIYA; Kazunori OISHI; Kazunori TOMONO; Kazuo MIZUKOSHI; Kazuo SAKAMOTO; Kazuo SASAYAMA; Kazuo SATO; Kazuo TAKEBE; Kazuo TANIFUJI; Kazuyoshi WATANABE; Keiichiro MATSUNAGA; Keiji TAKAHASHI; Keisuke TAKEUCHI; Keizo MATSUMOTO; Keizo YAMAGUCHI; Ken OSONOI; Kenichi HOSOYA; Kenichi IMAMURA; Kenichi KIMURA; Kenichi TAKAHASHI; Kenichi TAKEUCHI; Kenji HASEGAWA; Kentaro WATANABE; Kihachiro SHIMIZU; Kikuo OHNUMA; Kiyo NISHIOKA; Kiyoshi KONNO; Kohei HARA; Kohya SHIBA; Koichi WADA; Koichiro NAKATA; Koji TAKAGI; Kotaro OIZUMI; Kou MUROHASHI; Kouhei ISHIMARU; Kumi KOKUBU; Kunihiko YOSHIMURA; Kuninori TSUKIYAMA; Makoto NAKAZONO; Makoto SEKINE; Makoto TAKANO; Masaaki ARAKAWA; Masahide KAWAHIRA; Masahide SHINOHARA; Masahiko TOMIYAMA; Masahito KATO; Masaki HIROTA; Masako SASAKI; Masamitus NAKAJIMA; Masamoto NAKANO; Masanaga TAKATO; Masao TAMURA; Masaru FUJINE; Masaru KOYAMA; Masaru NASU; Masashi YAMAMOTO; Masataka KATSU; Masato HAYASHI; Masatoshi WATANABE; Masayoshi INAGAKI; Masayuki ANDO; Masayuki NOGUCHI; Masumi BABA; Masumi TOMIZAWA; Michio YAMAKIDO; Mikiya SATO; Mitsuhide OHMICHI; Mitsuo MASUDA; Mitsuru HAYASE; Miyako MASAKI; Miyoko ITASAKA; Miyoko SAITOU; Morio SAGARA; Moritaka SUGA; Munetaka KOMORI; Naofumi SUYAMA; Naohiko CHONABAYASHI; Naoki TAMAZAWA; Naomi ITO; Naoto KITAMURA; Nobuhisa SATO; Nobuki AOKI; Nobuo OHYA; Norio NOZUE; Osamu HOSONO; Osamu KIMURA; Osamu KURIMURA; Osamu UEHARA; Reiko ONO; Rinzo SOEJIMA; Satoru ADACHI; Seiichi AONUMA; Seiichi MURAKAMI; Shigeki HAYASHI; Shigeki ODAGIRI; Shigenobu UMEKI; Shin KAWAI; Shinichi TANIZAWA; Shinji OKUI; Shirou KOSAKA; Shoichi SASAOKA; Shukuro ARAKI; Shunichi ISHII; Sigeru KOHNO; Soichiro UEHARA; Susumu YAGI; Tadashi MIYAHARA; Tadashi MIYAZAWA; Takahiko KAWAGISHI; Takao OKUBO; Takao SASAKI; Takashi ITO; Takayoshi TASHIRO; Takeshi KAWAI; Tamotsu TAKISHIMA; Tatsuo KATO; Tatsuo NAKATANI; Tohru ABE; Tomoo KOHARA; Toshiaki HAGA; Toshiaki HAYASHI; Toshiharu ITO; Toshihiko TAKEUCHI; Toshimi OKUSHIMA; Toshio FUKUI; Toshiyuki YAMAMOTO; Toyokazu TAMURA; Tsukasa YOSHIDA; Yasufumi MIYAMOTO; Yasuharu MASUYAMA; Yasumasa DOTSU; Yasuo MATSUOKA; Yasuo ONO; Yasuo TANNO; Yasushi UEDA; Yasuyuki SATO; Yohmei HIRAGA; Yoichiro GOTO; Yoshiaki KAWAGUCHI; Yoshiharu AMASAKI; Yoshihiro HONDA; Yoshihiro YOKOTA; Yoshiji YAMANE; Yoshikazu TASAKA; Yoshio KAWASE; Yoshio KOBAYASHI; Yoshio UZUKA; Yoshiro SAWAE; Yoshitaka NAKAMORI; Yoshito NIKI; Yoshiyasu IKUNO; Yuichi INOUE; Yuichiro UEDA; Yuji SUGIMOTO; Yuji WATANUKI; Yukio MATSUMOTO; Yutaka HITSUDA; Yutaka TOKUE; Yuzo FUNATSU; 三木 文雄; 上原 修; 上原 総一郎; 上田 泰; 上田 雄一郎; 上綱 昭光; 上野 勝則; 中園 誠; 中山 一朗; 中島 正光; 中森 祥隆; 中田 紘一郎; 中谷 龍王; 中野 正心; 丹野 恭夫; 二木 芳人; 井上 尚志; 井上 祐一; 井上 英二; 今村 憲市; 今野 淳; 伊藤 利治; 伊藤 直美; 伊藤 章; 伊藤 隆司; 佐々木 孝夫; 佐々木 昌子; 佐々木 英夫; 佐藤 信久; 佐藤 和男; 佐藤 幹弥; 佐藤 靖之; 倉光 宏; 冨山 誠彦; 副島 林造; 加藤 政仁; 加藤 達夫; 加藤 錠一; 勝 正孝; 北村 直人; 原 耕平; 古賀 宏延; 吉村 邦彦; 吉田 司; 和田 光一; 国部 久美; 坂元 一夫; 増山 泰治; 増本 英男; 増田 光男; 大久保 隆男; 大山 馨; 大沼 菊夫; 大泉 耕太郎; 大石 和徳; 大谷 信夫; 大道 光秀; 天崎 吉晴; 奥井 津二; 奥嶋 敏美; 宇塚 良夫; 守屋 克良; 安倍 達; 安岡 彰; 安藤 正幸; 宍戸 春美; 室橋 光宇; 宮 一路; 宮下 英夫; 宮原 正; 宮本 康文; 宮沢 正; 富沢 磨須美; 小原 共雄; 小坂 志朗; 小山 優; 小林 仁; 小林 宏行; 小林 芳夫; 小森 宗敬; 小田切 繁樹; 小野 玲子; 尾仲 章男; 山口 恵三; 山木 泉; 山木戸 道郎; 山本 俊幸; 山本 和英; 山本 眞志; 山根 至二; 岡本 勝博; 島田 馨; 嶋田 甚五郎; 川口 義明; 川岸 隆彦; 川平 昌秀; 川根 博司; 平位 広章; 平山 亮夫; 平賀 洋明; 広田 正毅; 後藤 純; 後藤 陽一郎; 徳江 豊; 押谷 浩; 斉藤 三代子; 斎藤 篤; 斧 康雄; 日野 二郎; 早瀬 満; 朝野 和典; 木村 修; 木村 健一; 本田 芳宏; 杉本 勇二; 村上 誠一; 村岡 啓; 村田 哲人; 東 冬彦; 松岡 康夫; 松本 慶蔵; 松本 文夫; 松本 行雄; 松永 敬一郎; 板坂 美代子; 林 敏明; 林 泉; 林 茂樹; 林 雅人; 柴 孝也; 栗村 統; 梅木 茂宣; 横田 幸弘; 櫃田 豊; 武内 俊彦; 武内 健一; 武内 恵輔; 武部 和夫; 水越 和夫; 池本 秀雄; 池田 英樹; 河合 伸; 河合 健; 河瀬 吉雄; 河辺 博史; 河野 茂; 沼田 博行; 深谷 一太; 清水 喜八郎; 渡辺 一功; 渡辺 健太郎; 渡辺 彰; 渡辺 正俊; 澤江 義郎; 瀧島 任; 熊野 博之; 玉沢 直樹; 生野 善康; 田代 隆良; 田坂 佳千; 田村 昌士; 田村 豊一; 皆上 宏俊; 相楽 衛男; 真崎 美矢子; 矢木 晋; 石丸 浩平; 石井 俊一; 神垣 郁夫; 福井 俊夫; 福原 弘文; 稲垣 正義; 笹山 一夫; 笹岡 彰一; 築山 邦規; 篠原 正英; 細谷 賢一; 細野 治; 綿貫 祐司; 船津 雄三; 花木 英和; 芳賀 敏昭; 荒川 正昭; 荒木 淑郎; 菅 守隆; 藤根 勝; 藤森 一平; 蝶名林 直彦; 衣川 文明; 西岡 きよ; 西谷 肇; 谷本 普一; 谷澤 伸一; 谷藤 一生; 足立 暁; 遅野井 健; 道津 安正; 遠藤 勝美; 那須 勝; 重野 秀明; 野口 昌幸; 野末 則夫; 金山 広海; 鈴木 周雄; 鈴木 幹三; 長谷川 健司; 関根 理; 青木 信樹; 青沼 清一; 須山 尚史; 馬場 ますみ; 高木 宏治; 高橋 健一; 高橋 敬治; 高橋 淳; 高野 慎; 高頭 正長; 齋藤 玲
Source
感染症学雑誌 / Kansenshogaku Zasshi. 1989, 63(4):318
Subject
Language
Japanese
ISSN
0387-5911
1884-569X
1884-569X
Abstract
The clinical efficacy and safety of Cefodizime (CDZM), a new cephem antibiotic, was objectively compared with that of Cefotaxime (CTX) in patients with respiratory infections under a wellcontrolled comparative study.Patients were administered CDZM or CTX by drip infusion b. i. d. for 14 days in principle at a daily dose of two grams.The parameters assessed were clinical efficacy, icacy, safety and clinical usefulness.The following results were obtained:1. On the basis of committee judgement the clinical efficacy rate was 78.1%(125/160) for the CDZM group, 82.7%(124/150) for the CTX group, and no significant difference was observed between the two drug groups. On the other hand, on the basisofjudgement by physicians in charge, the clinical efficacy rate was 83.1%(133/160) for the CDZM group, 83.9%(125/149) for the CTX group, and no significant difference was observed between the two groups.2. The corresponding figures for patients with pneumonia and pulmonary suppuration were 82.4%(70/85) for the CDZM group, 79.7%(59/74) for the CTX group and no significant difference was observed according to the committee judgement. The judgement by physicians in charge also revealed 83.5%(71/85) for the CDZM group and 82.2%(60/73) for the CTX group. No.significant difference was noted between the two groups. While, the committee judgement for the clinical efficacy in patients with chronic respiratory tract infections showed 73.3%(55/75) for the CDZM group, 85.5%(65/76) for the CTX group, and no significant difference was observed between the two drug groups. The corresponding figures were 82.7%(62/75) for the CDZM group, 85.5%(65/76) for the CTX group, and no significant difference was observed between the two drug groups on the judgement by physicians in charge.Furthermore, the clinical efficacy of both drugs on chronic respiratory tract infections was assessed according to “Criteria for Evaluation of Clinical Efficacy of Chemotherapeutics on Chronic Respiratory Tract Infection”. It was 76.8%(53/69) for the CDZM group, 76.3%(58/76) for the CTX group, and no significant difference was observed between the two groups.3. The bacteriological eradication rate of causative pathogens was 92.4% out of 66 patients treated with CDZM and 95.5% out of 67 patients treated with CTX in whom judgement was possible. No significant difference was observed between the two drug groups.4. The adverse reactions occurred in 4 (2.2%) patients for the CDZM group and 8 (4.5%) patients for the CTX group respectively, with no significant inter-group difference in frequency of these reactions for all cases. But the adverse reactions classified by pneumonia and pulmonary suppuration occurred in no patients for the CDZM group and 4 (5.1%) for the CTX group, with significantly less incidence in the former than the latter (p<0.05). The abnormal changes in laboratory findings were observed in 26.6%(45/169) for the CDZM group and 24.1%(39/162) for the CTX group, with no significant difference between the two groups for all cases.5. There was no significant difference in the utility between the two groups for all cases, pneumonia, pulmonary suppuration and chronic respiratory tract infection groups according to both the commitee judgement and physicians' one.Thus, it was concluded that CDZM is a drug with clinically high usefulness by the overall assessment on the basis of clinical efficacy and safety.